Document:

EX-10.10

 Exhibit 10.10 

FIRST AMENDMENT TO LEASE 

This First Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 14, 2016
(the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and ARMO BIOSCIENCES, INC., a Delaware corporation (“Tenant), with reference to the
following facts (“Recitals”): 
 A.    Landlord and Tenant are the parties to that certain
Lease, dated February 19, 2013, entered into by and between Tenant, as tenant, and Landlord, as landlord (the “Existing Lease”), for certain “Premises” described therein containing approximately 11,305
rentable square feet of the Building (located at 575 Chesapeake Drive, Redwood City, California), all as more particularly described in the Existing Lease. 

B.    Landlord and Tenant desire to provide for (i) the extension of the Term of the Existing Lease; and
(ii) other amendments of the Existing Lease as more particularly set forth below. 
 NOW, THEREFORE, in consideration of the foregoing,
and of the mutual covenants set forth herein and of other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1.    SCOPE OF AMENDMENT; DEFINED TERMS. Except as expressly provided in this Amendment, the Existing Lease shall remain in
full force and effect. Should any inconsistency arise between this Amendment and the Existing Lease as to the specific matters which are the subject of this Amendment, the terms and conditions of this Amendment shall control. All capitalized terms
used in this Amendment and not defined herein shall have the meanings set forth in the Existing Lease unless the context clearly requires otherwise; provided, however, that the term “Lease” as used herein and, from and after the
Execution Date, in the Existing Lease shall refer to the Existing Lease as modified by this Amendment. 
 SECTION
2.    REMEASUREMENT. Landlord and Tenant acknowledge and agree that Landlord has remeasured the Premises, and that, according to such remeasurement, the rentable square footage of the Premises is 11,388 and accordingly,
effective as of the Extension Commencement Date (as defined below), and continuing throughout the Extended Term (as defined below), all references to the “Rentable Area of the Premises” in the Lease are
hereby amended to refer to “11,388 square feet”. 
 SECTION 3.    EXTENSION OF TERM. Landlord and
Tenant acknowledge and agree that, notwithstanding any provision of the Existing Lease to the contrary, the current Term pursuant to the Existing Lease will expire on May 18, 2017, and that the Term of the Lease is hereby extended for the
period of sixty (60) months (the “Extended Term”) commencing on May 19, 2017 (the “Extension Commencement Date”) and expiring May 18, 2022 (hereafter, the “Expiration
Date” in lieu of the date provided in the Existing Lease), unless sooner terminated pursuant to the terms of the Lease. Landlord and Tenant acknowledge and agree that this Amendment provides all rights and obligations of the parties with
respect to the Extended Term, whether or not in accordance with any other provisions, if any, of the Existing Lease regarding renewal or extension; provided however, the Option to Extend set forth in Section 4 of Rider 2 of the Existing Lease
shall apply to extend the Extended Term instead of the initial Term, and the phrase “Extended Term” is inserted in place of references to the “initial Term” in the Option to Extend, and the Option Term
shall be for an additional five (5) year period instead of an additional three (3) year period. 

 SECTION 4.    MONTHLY BASE RENT FOR EXTENDED TERM. Notwithstanding any provision of
the Existing Lease to the contrary, commencing on the Extension Commencement Date and continuing through the Expiration Date of the Extended Term, the amount of Monthly Base Rent payable by Tenant for the Premises shall be as follows: 

 

					
	 Period from/to
	  	Monthly Base Rent	 
	 May 19, 2017 to May 18, 2018
	  	$	42,705.00	 
	 May 19, 2018 to May 18, 2019
	  	$	43,986.15	 
	 May 19, 2019 to May 18, 2020
	  	$	45,305.73	 
	 May 19, 2020 to May 18, 2021
	  	$	46,664.91	 
	 May 19, 2021 to May 18, 2022
	  	$	48,064.85	 

 SECTION 5.    TENANT’S SHARE. During the Extended Term, Tenant shall pay all Additional Rent
payable under the Lease, including Tenant’s Share of Operating Expenses. Notwithstanding any provisions of the Existing Lease to the contrary, Tenant’s Building Share shall continue to be 29.86%, Tenant’s Phase Share shall continue to
be 3.75% and Tenant’s Project Share shall continue to be 2.10%, as set forth in the Existing Lease. 
 SECTION
6.    “AS IS” CONDITION. 

(a)    Notwithstanding any provision of the Existing Lease to the contrary, Tenant hereby leases for the Extended Term and
accepts the Premises in its “AS IS” condition existing on the Execution Date, without any express or implied representations or warranties of any kind by Landlord, its brokers, manager or agents, or the employees of any of
them regarding the Premises; and Landlord shall not have any obligation to construct or install any tenant improvements or alterations or to pay for any such construction or installation, except as expressly set forth in Subsection (b) below.

 (b)    Landlord shall provide Tenant with an improvement allowance for the Premises as set forth in the Workletter
set forth in Exhibit A hereto (the “Workletter”). 
 SECTION 7.    LIMITATION OF LANDLORD’S LIABILITY.
Notwithstanding any provision of the Existing Lease to the contrary (including, without limitation, Section 27.08 of the Existing Lease), Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or obligation
of Landlord in connection with this Lease shall only be enforced against Landlord’s equity interests in the Project up to a maximum of Two Million Dollars ($2,000,000.00) and in no event against any other assets of the Landlord, or
Landlord’s officers or directors or partners, and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall not be entitled to any judgment in excess of such amount. 

SECTION 8.    TIME OF ESSENCE. Without limiting the generality of any other provision of the Existing Lease, time is of the essence
to each and every term and condition of this Amendment. 
 SECTION 9.    BROKERS. Notwithstanding any other provision of the
Existing Lease to the contrary, Tenant represents that in connection with this Amendment it is represented by Jones Lang LaSalle (“Tenant’s Broker”) and, except for Tenant’s Broker and Newmark Cornish &
Carey (“Landlord’s Broker”), Tenant has not dealt with any real estate broker, sales person, or finder in connection with this Amendment, and no such person initiated or participated in the negotiation of this Amendment.
Tenant hereby indemnifies and agrees to protect, defend and hold Landlord harmless from and against all claims, losses, damages, liability, costs and expenses (including, without limitation, attorneys’ fees and expenses) by virtue of any
broker, agent or other person claiming a commission or other form of compensation by virtue of alleged representation of, or dealings or discussions with Tenant with respect to the subject matter of this Amendment, except for Tenant’s Broker
and Landlord’s Broker. Tenant is not obligated to pay or fund any amount to Landlord’s Broker or Tenant’s Broker, and Landlord hereby agrees to pay such commission, if any, to which Landlord’s Broker and Tenant’s Broker are
entitled in connection with the subject matter of this Amendment pursuant to Landlord’s separate written agreement with Landlord’s Broker. The provisions of this Section shall survive the expiration or earlier termination of the Lease.

  
 2 

 SECTION 10.    ATTORNEYS’ FEES. Each party to this Amendment shall bear its own
attorneys’ fees and costs incurred in connection with the discussions preceding, negotiations for and documentation of this Amendment. In the event that either party brings any suit or other proceeding with respect to the subject matter or
enforcement of this Amendment or the Lease, the parties acknowledge and agree that the provisions of Section 11.03 of the Existing Lease shall apply. 

SECTION 11.    EFFECT OF HEADINGS; RECITALS: EXHIBITS. The titles or headings of the various parts or sections hereof are intended
solely for convenience and are not intended and shall not be deemed to or in any way be used to modify, explain or place any construction upon any of the provisions of this Amendment. Any and all Recitals set forth at the beginning of this Amendment
are true and correct and constitute a part of this Amendment as if they had been set forth as covenants herein. Exhibits, schedules, plats and riders hereto which are referred to herein are a part of this Amendment. 

SECTION 12.    ENTIRE AGREEMENT; AMENDMENT. This Amendment taken together with the Existing Lease, together with all exhibits,
schedules, riders and addenda to each, constitutes the full and complete agreement and understanding between the parties hereto and shall supersede all prior communications, representations, understandings or agreements, if any, whether oral or
written, concerning the subject matter contained in this Amendment and the Existing Lease, as so amended, and no provision of the Lease as so amended may be modified, amended, waived or discharged, in whole or in part, except by a written instrument
executed by all of the parties hereto. 
 SECTION 13.    OFAC. Landlord advises Tenant hereby that the purpose of this Section is
to provide to the Landlord information and assurances to enable Landlord to comply with the law relating to OFAC. 
 Tenant hereby represents, warrants and
covenants to Landlord, either that (i) Tenant is regulated by the SEC, FINRA or the Federal Reserve (a “Regulated Entity”) or (ii) neither Tenant nor any person or entity that directly or indirectly
(a) controls Tenant or (b) has an ownership interest in Tenant of twenty-five percent (25%) or more, appears on the list of Specially Designated Nationals and Blocked Persons (“OFAC List”) published by the Office of
Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury. 
 If, in connection with the Lease, there is one or more
Guarantors of Tenant’s obligations under the Lease, then Tenant further represents, warrants and covenants either that (i) any such Guarantor is a Regulated Entity or (ii) neither Guarantor nor any person or entity that directly or
indirectly (a) controls such Guarantor or (b) has an ownership interest in such Guarantor of twenty-five percent (25%) or more, appears on the OFAC List. 

Tenant covenants that during the term of the Lease to provide to Landlord information reasonably requested by Landlord including without limitation,
organizational structural charts and organizational documents which Landlord may deem to be necessary (“Tenant OFAC Information”) in order for Landlord to confirm Tenant’s continuing compliance with the provisions
of this Section. Tenant represents and warrants that the Tenant OFAC Information it has provided or to be provided to Landlord or Landlord’s Broker in connection with the execution of this Amendment is true and complete. 

SECTION 14.    RATIFICATION. Landlord and Tenant represent to each other that (a) the Existing Lease is in full force and
effect and has not been modified except as provided by this Amendment; and (b) as of the Execution Date, there are no uncured defaults or unfulfilled obligations on the part of Landlord or Tenant. Tenant represents to Landlord that Tenant is
currently in possession of the entire Premises as of the Execution Date, and neither the Premises, nor any part thereof, is occupied by any subtenant or other party other than Tenant. 

SECTION 15.    AUTHORITY. Each party represents and warrants to the other that it has full authority and power to enter into and
perform its obligations under this Amendment, that the person executing this Amendment is fully empowered to do so, and that no consent or authorization is necessary from any third party. Landlord may request that Tenant provide Landlord evidence of
Tenant’s authority. 
 SECTION 16.    DISCLOSURE REGARDING CERTIFIED ACCESS SPECIALIST. Pursuant to California Civil Code
Section 1938, Landlord hereby notifies Tenant that as of the date of this Amendment, the Premises has not undergone inspection by a “Certified Access Specialist” to determine whether the Premises meet all
applicable construction-related accessibility standards under California Civil Code Section 55.53. 

  
 3 

 SECTION 17.    ENERGY UTILITY USAGE. If Tenant is billed directly by a public utility
with respect to Tenant’s energy usage at the Premises, then, upon request, Tenant shall provide monthly energy utility usage for the Premises to Landlord for the period of time requested by Landlord (in electronic or paper format) or, at
Landlord’s option, provide any written authorization or other documentation required for Landlord to request information regarding Tenant’s energy usage with respect to the Premises directly from the applicable utility company. 

SECTION 18.    COUNTERPARTS. This Amendment may be executed in duplicates or counterparts, or both, and such duplicates or
counterparts together shall constitute but one original of the Amendment, and the signature of any party to any counterpart shall be deemed a signature to, and may be appended to, any other counterpart. Each duplicate and counterpart shall be
equally admissible in evidence, and each original shall fully bind each party who has executed it. 
  

							
	IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set forth above.
			
	TENANT	 		 	COMPANY:
		 		 	a Delaware corporation
				
		 		 	By:	 	 /s/ Peter Van Vlasselaer

		 		 	Print Name:	 	Peter Van Vlasselaer
		 		 	Title:	 	CEO and President
		 		 	(Chairman of Board, President or Vice President)
				
		 		 	By:	 	  

		 		 	Print Name:	 	  

		 		 	Title:	 	  

		 		 	(Secretary, Assistant Secretary, CFO or Assistant Treasurer)
			
	LANDLORD	 		 	METROPOLITAN LIFE INSURANCE COMPANY,
		 		 	a New York corporation
				
		 		 	By:	 	 /s/ Leland Low

		 		 	Print Name:	 	Leland Low
		 		 	Title:	 	Director
		 		 	(Chairman of Board, President or Vice President)

  
 4 

 EXHIBIT A 

WORKLETTER AGREEMENT 

(Allowance) 
 This Workletter Agreement
(“Workletter”) is attached to and a part of a certain First Amendment to Lease by and between Metropolitan Life Insurance Company, a New York corporation, as Landlord, and Armo Biosciences, Inc., a Delaware corporation, as Tenant,
for the Premises (the “Amendment”). Terms used herein and not defined herein shall have the meaning of such terms as defined elsewhere in the Amendment. For purposes of this Workletter, references to “State” and
“City” shall mean the State and City in which the Building is located. 
 1.    Landlord Work. 

Landlord shall have no obligation to perform any work. 

2.    Tenant’s Plans. 

2.1.    Description. At its expense, Tenant shall employ: 

(i)    one or more architects reasonably satisfactory to Landlord and licensed by the State
(“Tenant’s Architect”) to prepare architectural drawings and specifications for all layout and Premises improvements not included in, or requiring any change or addition to, the AS IS condition and Landlord Work, if any.

 (ii)    one or more engineers reasonably satisfactory to Landlord and licensed by the State
(“Tenant’s Engineers”) to prepare structural, mechanical and electrical working drawings and specifications for all Premises improvements not included in, or requiring any change or addition to, the AS IS condition and
Landlord Work, if any. 
 All such drawings and specifications are referred to herein as “Tenant’s Plans”. Tenant’s Plans
shall be in form and detail sufficient to secure all applicable governmental approvals. Tenant’s Architect shall be responsible for coordination of all engineering work for Tenant’s Plans and shall coordinate with any consultants retained
by Tenant in connection with the design and installation of improvements to the Premises (the use of such consultants is subject to Landlord’s consent), and Landlord’s architect or other representative to assure the consistency of
Tenant’s Plans with the Base Building Work and Landlord Work (if any). 
 Tenant shall pay Landlord, within twenty (20) days of receipt of each
invoice from Landlord, the cost incurred by Landlord for Landlord’s architects and engineers to review Tenant’s Plans for consistency of same with the Base Building Work and Landlord Work, if any, to the extent such cost is Excess Cost (as
defined below). Tenant’s Plans shall also include the following: 
 (a)    Final Space Plan: The “Final Space
Plan” for the Premises shall include a full and accurate description of room titles, floor loads, alterations to the Base Building or Landlord Work (if any) or requiring any change or addition to the AS IS condition, and the dimensions
and location of all partitions, doors, aisles, plumbing (and furniture and equipment to the extent same affect floor loading). The Final Space Plan shall (i) be compatible with the design, construction, systems and equipment of the Base
Building and Landlord Work, if any; (ii) specify only materials, equipment and installations which are new and of a grade and quality no less than existing components of the Building when they were originally installed (collectively,
(i) and (ii) may be referred to as “Building Standard” or “Building Standards”); (iii) comply with Laws, (iv) be capable of logical measurement and construction, and (v) contain all such
information as may be required for the preparation of the Mechanical and Electrical Working Drawings and Specifications (including, without limitation, a capacity and usage report, from engineers designated by Landlord pursuant to
Section 3.1(b). below, for all mechanical and electrical systems in the Premises). 

  
 Exhibit A – Page 1

 (b)    Mechanical and Electrical Working Drawings and
Specifications: Tenant shall employ engineers approved by Landlord to prepare Mechanical and Electrical Working Drawings and Specifications showing complete plans for electrical, life safety, automation, plumbing, water, and air cooling,
ventilating, heating and temperature control and shall employ engineers designated by Landlord to prepare for Landlord a capacity and usage report (“Capacity Report”) for all mechanical and electrical systems in the Premises.

 (c)    Issued for Construction Documents: The “Issued for Construction
Documents” shall consist of all drawings (1/8” scale) and specifications necessary to construct all Premises improvements including, without limitation, architectural and structural working drawings and specifications and Mechanical
and Electrical Working Drawings and Specifications and all applicable governmental authorities plan check corrections. 

2.2.    Approval by Landlord. Tenant’s Plans and any revisions thereof shall be subject to Landlord’s
approval, which approval or disapproval: 
 (i)    shall not be unreasonably withheld, provided however,
that Landlord may disapprove Tenant’s Plans in its sole and absolute discretion if they (a) adversely affect the structural integrity of the Building, including applicable floor loading capacity; (b) adversely affect any of the
Building Systems (as defined below), the Common Areas or any other tenant space (whether or not currently occupied); (c) fail to fully comply with Laws, (d) affect the exterior appearance of the Building; (e) provide for improvements which
do not meet or exceed the Building Standards; or (f) involve any installation on the roof, or otherwise affect the roof, roof membrane or any warranties regarding either. Building Systems collectively shall mean the structural, electrical,
mechanical (including, without limitation, heating, ventilating and air conditioning), plumbing, fire and life-safety (including, without limitation, fire protection system and any fire alarm), communication, utility, gas (if any), and security (if
any) systems in the Building. 
 (ii)    shall not be delayed beyond ten (10) business days with
respect to initial submissions and major change orders (those which impact Building Systems or any other item listed in subpart (i) of Section 3.2 above) and beyond five (5) business days with respect to required revisions and any
other change orders. 
 If Landlord disapproves of any of Tenant’s Plans, Landlord shall advise Tenant of what Landlord disapproves in reasonable
detail. After being so advised by Landlord, Tenant shall submit a redesign, incorporating the revisions required by Landlord, for Landlord’s approval. The approval procedure shall be repeated as necessary until Tenant’s Plans are
ultimately approved. Approval by Landlord shall not be deemed to be a representation or warranty by Landlord with respect to the safety, adequacy, correctness, efficiency or compliance with Laws of Tenant’s Plans. Tenant shall be fully and
solely responsible for the safety, adequacy, correctness and efficiency of Tenant’s Plans and for the compliance of Tenant’s Plans with any and all Laws. 

2.3.    Landlord Cooperation. Landlord shall cooperate with Tenant and make good faith efforts to
coordinate Landlord’s construction review procedures to expedite the planning, commencement, progress and completion of Tenant Work. Landlord shall complete its review of each stage of Tenant’s Plans and any revisions thereof and
communicate the results of such review within the time periods set forth in Section 3.2 above. 

2.4.    City Requirements. Any changes in Tenant’s Plans which are made in response to
requirements of the applicable governmental authorities and/or changes which affect the Base Building Work shall be immediately submitted to Landlord for Landlord’s review and approval. 

2.5.    “As-Built”
Drawings and Specifications. A CADD-DXF diskette file and a set of black line drawings of all “as-built” drawings and specifications of
Tenant’s Work in the Premises (reflecting all field changes and including, without limitation, architectural, structural, mechanical and electrical drawings and specifications) prepared by Tenant’s Architect and Engineers or by Contractors
(defined below) shall be delivered by Tenant at Tenant’s expense to the Landlord within thirty (30) days after completion of the Tenant Work. If Landlord has not received such drawings and diskette(s) within thirty (30) days, Landlord
may give Tenant written notice of such failure. If Tenant does not produce the drawings and diskette(s) within ten (10) days after Landlord’s written notice, Landlord may, at Tenant’s sole cost which may be deducted from the
Allowance, produce the drawings and diskette(s) using Landlord’s personnel, managers, and outside consultants and contractors. Landlord shall receive an hourly rate reasonable for such production. 

  
 Exhibit A – Page 2

 3.    Tenant Work. 

3.1.    Tenant Work Defined. All tenant improvement work required by the Issued for Construction Documents
(including, without limitation, any approved changes, additions or alterations pursuant to Section 6 below) is referred to in this Workletter as “Tenant Work.” 

3.2.    Tenant to Construct. Tenant shall construct all Tenant Work pursuant to this Workletter, and except to the
extent modified by or inconsistent with express provisions of this Workletter, pursuant with the provisions of the terms and conditions of Article Nine of the Lease, governing Tenant Alterations (except to the extent modified by this Workletter) and
all such Tenant Work shall be considered “Tenant Alterations” for purposes of the Lease. 

3.3.    Construction Contract. All contracts and subcontracts for Tenant Work shall include any terms and
conditions reasonably required by Landlord. 
 3.4.    Contractor. Tenant shall select one or more contractors to
perform the Tenant Work (“Contractor”) subject to Landlord’s prior written approval, which shall not unreasonably be withheld. 

3.5.    Division of Landlord Work and Tenant Work. Tenant Work is defined in Section 3.1 above and Landlord
Work, if any, is defined in Section 1. 
 4.    Tenant’s Expense. 

Tenant agrees to pay for all Tenant Work, including, without limitation, the costs of design thereof, whether or not all such costs are
included in the “Permanent Improvement Costs” (defined below). Subject to the terms and conditions of this Workletter, Tenant shall apply the “Allowance” (defined below) to payment of the Permanent
Improvement Costs and Tenant’s FF&E (as defined below). Landlord shall provide Tenant a tenant improvement allowance (“Allowance”) at the rate of Tent Dollars ($10.00) per square foot of Rentable Area of the Premises. The
Allowance shall be used solely to reimburse Tenant for the Permanent Improvement Costs and Tenant’s FF&E. The term “Permanent Improvement Costs” shall mean the actual and reasonable costs of construction of
that Tenant Work which constitutes permanent improvements to the Premises, actual and reasonable costs of design thereof and governmental permits therefor, costs incurred by Landlord for Landlord’s architects and engineers pursuant to
Section 2.1, and Landlord’s construction administration fee (defined in Section 7.8 below). Tenant may, upon written application to Landlord, use the remaining Allowance, if any, to reimburse Tenant for the costs of acquiring and
installing Tenant’s FF&E in the Premises. For purposes of this Workletter, “Tenant’s FF&E” shall mean Tenant’s furniture, furnishings, telephone systems, computer systems, equipment, cubicles and any
other personal property or fixtures, and installation thereof. If Tenant does not utilize one hundred percent (100%) of the Allowance for Permanent Improvement Costs and/or Tenant’s FF&E no later than December 31, 2017, Tenant shall
have no right to the unused portion of the Allowance and in no event shall Landlord be required to disburse any portion of the Allowance prior to January 1, 2017. 

5.    Application and Disbursement of the Allowance. 

5.1.    Tenant shall prepare a budget for all Tenant Work, including the Permanent Improvement Costs and all other costs of
the Tenant Work (“Budget”), which Budget shall be subject to the reasonable Retention” (defined below). “Landlord’s Retention” shall mean an amount equal to ten percent (10%) of the
Allowance, which Landlord shall retain out of the Allowance and shall not be obligated to disburse unless and until after Tenant has completed the Tenant Work and complied with Section 5.4 below. Further, Landlord shall not be obligated to make
any disbursement of the Allowance unless and until Tenant has provided Landlord with (i) bills and invoices covering all labor and material expended and used in connection with the particular portion of the Tenant Work and Tenant’s
FF&E for which Tenant has requested reimbursement, (ii) an affidavit from Tenant stating that all of such bills and invoices have either been paid in full by Tenant or are due and owing, and all such costs qualify as Permanent Improvement
Costs, (iii) contractors affidavit covering all labor and materials expended and used, (iv) Tenant, contractors and architectural completion affidavits (as applicable), and (v) valid mechanics’ lien releases and waivers
pertaining to any completed portion of the Tenant Work which shall be conditional or unconditional, as applicable, all as provided pursuant to Section 5.2 and 5.4 below. 

  
 Exhibit A – Page 3

 5.2.    Upon Tenant’s full compliance with the provisions of
Section 5, and if Landlord determines that there are no applicable or claimed stop notices (or any other statutory or equitable liens of anyone performing any of Tenant Work or providing materials for Tenant Work) or actions thereon, Landlord
shall disburse the applicable portion of the Allowance relating to the Permanent Improvement Costs as follows: 

(a)    In the event of conditional releases, to the respective contractor, subcontractor, vendor, or other
person who has provided labor and/or services in connection with the Tenant Work, upon the following terms and conditions: (i) such costs are Permanent Improvement Costs, are covered by the Allowance, and Tenant has completed and delivered to
Landlord a written request for payment, in form reasonably approved by Landlord, setting forth the exact name of the contractor, subcontractor or vendor to whom payment is to be made and the date and amount of the bill or invoice, (ii) the
request for payment is accompanied by the documentation set forth in Section 5.1; and (iii) Landlord, or Landlord’s appointed representative, has inspected and reasonably approved the work for which Tenant seeks payment (provided that
Landlord or its representative failure to inspect and approve the work within ten (10) days of request shall be deemed Landlord’s approval of the work); or 

(b)    In the event of unconditional releases, directly to Tenant upon the following terms and conditions:
(i) Tenant seeks reimbursement for costs of Tenant Work which have been paid by Tenant are Permanent Improvement Costs, and are covered by the Allowance; (ii) Tenant has completed and delivered to Landlord a request for payment, in form
reasonably approved by Landlord, setting forth the name of the contractor, subcontractor or vendor paid and the date of payment, (iii) the request for payment is accompanied by the documentation set forth in Section 5.1; and
(iv) Landlord, or Landlord’s appointed representative, has inspected and approved the work for which Tenant seeks reimbursement (provided that Landlord or its representative failure to inspect and approve the work within ten (10) days
of request shall be deemed Landlord’s approval of the work). 
 5.3.    Payment shall be made within thirty
(30) days following the date such documentation is provided. 
 5.4.    Prior to Landlord disbursing the
Landlord’s Retention to Tenant, Tenant shall submit to Landlord the following items within thirty (30) days after completion of the Tenant Work or such longer period as Landlord may permit: (i) “As Built” drawings
and specifications pursuant to Section 2.5 above, (ii) all unconditional lien releases from all general contractor(s) and subcontractor(s) performing work, (iii) a “Certificate of Completion” prepared by
Tenant’s Architect, and (iv) a final budget with supporting documentation detailing all costs associated with the Permanent Improvement Costs. 

5.5    After disbursement of the Allowance for the Permanent Improvement Costs, as provided above, Landlord shall disburse
the applicable portion of the remaining Allowance, if any, to Tenant for Tenant’s FF&E that Tenant properly requested and for which Tenant provided invoices. 

6.    Changes, Additions or Alterations. 

If Tenant desires to make any non-de minimis change, addition or alteration to the Tenant Work or
desires to make any change, addition or alteration to any of the Building Systems after approval of the Issued for Construction Documents, Tenant shall prepare and submit to Landlord plans and specifications with respect to such

  
 Exhibit A – Page 4

 
approval of Landlord. Such Budget shall be supported by a guaranteed maximum price construction or stipulated sum contract and such other documentation as Landlord may require to evidence the
total costs. To the extent the actual cost of the Permanent Improvement Costs exceeds the available Allowance (“Excess Cost”), Tenant shall be solely responsible for payment of such Excess Cost. Further, prior to any
disbursement of the Allowance by Landlord, Tenant shall pay and disburse its own funds for all that portion of the Permanent Improvement Costs equal to the sum of (a) the Permanent Improvement Costs in excess of the Allowance; plus (b) the
amount of “Landlord’s change, addition or alteration. Any such change, addition or alteration shall be subject to Landlord’s approval in accordance with the provisions of Section 2.2 of this Workletter.
Tenant shall be responsible for any submission to and plan check and permit requirements of the applicable governmental authorities. Tenant shall be responsible for payment of the cost of any such change, addition or alteration if it would result in
Excess Cost. 
 7.    Miscellaneous. 

7.1.    Scope. Except as otherwise set forth in the Lease, this Workletter shall not apply to any space added to the
Premises by Lease option or otherwise. 
 7.2.    If any Tenant Work includes any change, addition or alteration to the
following items, Tenant shall (at Tenant’s expense subject to application of the Allowance towards the costs of such items) adhere to the following standards for such items: 

(a)    Landlord approved lighting sensor controls as necessary to meet applicable Laws; 

(b)    Building Standard fluorescent fixtures in all Building office areas; 

(c)    Building Standard meters for each of electricity and chilled water used by Tenant shall be connected
to the Building’s system and shall be tested and certified prior to Tenant’s occupancy of the Premises by a State certified testing company; 

(d)    Building Standard ceiling systems (including tile and grid) and; 

(e)    Building Standard air conditioning distribution and Building Standard air terminal units. 

7.3.    Sprinklers. Subject to any terms, conditions and limitations set forth herein, Landlord shall provide an
operative sprinkler system consisting of mains, laterals, and heads “AS IS” on the date of delivery of the Premises to Tenant. Tenant shall pay for piping distribution, drops and relocation of, or additional, sprinkler system
heads and Building firehose or firehose valve cabinets, if Tenant’s Plans and/or any applicable Laws necessitate such. 

7.4.    Floor Loading. Floor loading capacity shall be within building design capacity. Tenant may exceed floor
loading capacity with Landlord’s consent, at Landlord’s sole discretion and must, at Tenant’s sole cost and expense, reinforce the floor as required for such excess loading. 

7.5.    Work Stoppages. If any work on the Real Property other than Tenant Work is delayed, stopped or otherwise
affected by construction of Tenant Work, Tenant shall immediately take those actions necessary or desirable to eliminate such delay, stoppage or effect on work on the Real Property other than Tenant Work. 

  
 Exhibit A – Page 5

 7.6.    Life Safety. Tenant (or Contractor) shall employ the services
of a fire and life-safety subcontractor reasonably satisfactory to Landlord for all fire and life-safety work at the Building. 

7.7.    Authorized Representatives. Tenant has designated Scott Ogg to act as Tenant’s representative with
respect to the matters set forth in this Workletter. Such representative(s) shall have full authority and responsibility to act on behalf of Tenant as required in this Workletter. Tenant may add or delete authorized representatives upon five
(5) business days’ notice to Landlord. 
 7.8.    Fee. Landlord shall receive a fee equal to not to
exceed two percent (2.0%) of the Allowance for Landlord’s review and supervision of construction of the Tenant Work, which fee shall be paid by Landlord applying two percent (2.0%) of the Allowance in payment thereof. Such fee is in addition to
Tenant’s reimbursement of costs incurred by Landlord pursuant to other provisions hereof, including, without limitation, for Landlord’s architects and engineers to review Tenants Plans. 

8.    Force and Effect. 

The terms and conditions of this Workletter shall be construed to be a part of the Lease and shall be deemed incorporated in the Lease by this
reference. Should any inconsistency arise between this Workletter and the Lease as to the specific matters which are the subject of this Workletter, the terms and conditions of this Workletter shall control. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 Exhibit A – Page 6EX-10.12

 Exhibit 10.12 

CONFIDENTIAL TREATMENT REQUESTED 

EXCLUSIVE PATENT LICENSE AGREEMENT 

by and between 
 MERCK,
SHARP & DOHME CORPORATION and 
 TARGENICS, Inc. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”), dated as of December 12, 2012 (the “Effective Date”), is
by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the
laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

WHEREAS, Merck has developed PEGylated human interleukin-10 polypeptide (PEG-IL10) and Merck is
seeking a licensee to develop and commercialize PEG-IL10; 
 WHEREAS, Licensee desires to develop and commercialize PEG-IL10; and 

WHEREAS, Licensee and Merck desire to enter into a license arrangement whereby Licensee will develop and commercialize PEG-IL10. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, Licensee and Merck hereby agree as
follows: 
 ARTICLE I – DEFINITIONS 

As used in this Agreement, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set
forth below: 
 1.01 “Affiliate” shall mean any individual or entity directly or indirectly controlling, controlled by or
under common control with a Party to this Agreement. For purposes of this Agreement, the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of an entity, or the right to receive fifty percent
(50%) or more of the profits or earnings of an entity shall be deemed to constitute control. Such other relationship as in fact results in actual control over the management, business and affairs of an entity shall also be deemed to constitute
control. 
 1.02 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending
on March 31, June 30, September 30 and December 31, for so long as this Agreement is in effect. 
 1.03
“Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31, for so long as this Agreement is in effect. 

1.04 “Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, and/or
Post-approval Clinical Trial. 
 1.05 “Combination Product” shall mean a Licensed Product which includes one or more active
ingredients, other than Licensed Compound, in combination with Licensed Compound. All references to Licensed Product in this Agreement shall be deemed to include Combination Product. 

  
 1 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.06 “Commercialization” shall mean, with respect to Licensed Product, any
and all activities directed to the marketing, promotion, distribution, offering for sale and selling such product, importing and exporting such product for sale, and interacting with Regulatory Authorities regarding the foregoing. Commercialization
shall also include Commercialization Studies. “Commercialize” has a correlative meaning. 
 1.07 “Commercialization
Studies” shall mean a study or data collection effort for the Licensed Product that is initiated in the Territory after receipt of Marketing Authorization for the Licensed Product and is principally intended to support the Commercialization
of the Licensed Product in the Territory; provided, that such study or data collection effort is not principally to support or maintain a Marketing Authorization or obtain a label change or maintain a label. 

1.08 “Compound Patent Rights” shall mean patents and patent applications that are listed on the attached Schedule A
(as well as substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or the
provisional applications of any such patents and patent applications; and foreign equivalents thereof) that, as of the Effective Date, are owned or controlled by Merck (and/or any of its Affiliates) having claims specifically covering the Licensed
Compound or the Manufacture and/or use thereof. 
 1.09 “Development” or “Develop” shall mean all
preclinical research and development activities and all clinical drug development activities, including, among other things: drug discovery, toxicology, formulation, statistical analysis and report writing, conducting clinical trials for the purpose
of obtaining and maintaining Marketing Authorization (including without limitation, post-marketing studies), and regulatory affairs related to all of the foregoing. Development shall include all clinical studies (including Phase III-B) that are
primarily intended to support or maintain a Marketing Authorization, maintain a label or obtain any label change, but shall exclude Commercialization Studies. 

1.10 “Diligent Efforts” shall mean [***]. 

1.11 “Field” shall mean the use of the Licensed Compound or the Licensed Product to treat or prevent any disease, disorder or
condition in humans only; except that it shall not include research, development, manufacture, import, marketing, distribution or sale of the Licensed Compound or Licensed Product for the acceleration or promotion of healing of wounds (including
chronic wounds), the prevention or reduction of scarring, or the treatment or prevention of fibrotic disorders; at any body sites. 
 1.12
“First Commercial Sale” shall mean, with respect to a country in the Territory, the first shipment of commercial quantities to a Third Party, of a Licensed Product sold in such country to a Third Party on arm’s length terms, by
Licensee, its Affiliate or sublicensee for use in the Field after the receipt of Marketing Authorization in such country. Sales for test marketing, sampling and promotional uses, Clinical Trial purposes or compassionate or similar use shall not be
considered to constitute a First Commercial Sale. 

  
 2 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.13 “Good Clinical Practices” shall mean the then current Good Clinical
Practices as such term is defined from time to time by the United States Food and Drug Administration (“FDA”) or other relevant governmental authority having jurisdiction over the Development, Manufacture or sale of Licensed Product in the
Territory pursuant to its regulations, guidelines or otherwise. 
 1.14 “Good Laboratory Practices” shall mean the current
good laboratory practice regulations of the FDA as described in the United States Code of Federal Regulations (“CFR”) or any comparable corresponding foreign regulations or their respective successor regulations. 

1.15 “Good Manufacturing Practices” shall mean the then current Good Manufacturing Practices as such term is defined from
time to time by the FDA or other relevant governmental authority having jurisdiction over the Development, Manufacture or sale of Licensed Product in the Territory pursuant to its regulations, guidelines or otherwise. 

1.16 “IND” shall mean an investigational new drug application with respect to the Licensed Product filed with the FDA for
beginning clinical trials in humans, or any comparable application filed with the Regulatory Authorities of a country other than the United States prior to beginning clinical trials in humans in that country, as well as all supplements or amendments
filed with respect to such filings. 
 1.17 “Know-How” shall mean any and all proprietary information and materials
(whether patentable or not) related to the Licensed Compound, Licensed Product, any Combination Product, formulation, product improvement and/or indication, or the Development, Manufacture or use of any of the foregoing, that are not in the public
domain, including, without limitation, (a) ideas, discoveries, inventions, improvements, technology or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components or compositions, (c) methods,
procedures, formulas, processes, tests, assays, techniques, regulatory requirements and strategies, (d) biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, Manufacturing and quality
control data and information related thereto, (e) technical and non-technical data and other information related to the foregoing, (f) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating
to such information or materials and (g) all applications, registrations, licenses, authorizations, approvals and correspondence relating to the Licensed Compound and/or Licensed Product submitted to Regulatory Authorities. 

1.18 “Licensee” shall have the meaning given to such term in the preamble of this Agreement. 

1.19 “Licensee Know-How” shall mean any and all Know-How developed by Licensee and/or any of its Affiliates or sublicensees
after the Effective Date. 

  
 3 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.20 “Licensee Patent Rights” shall mean patents and patent applications (as
well as substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or the provisional
applications of any such patents and patent applications; and foreign equivalents thereof) that, as of the Effective Date, are owned or controlled by Licensee (and/or any of its Affiliates) having claims specifically covering the Licensed Compound
or the Manufacture and/or use thereof. 
 1.21 “Licensed Compound” shall mean PEG-IL10. 

1.22 “Licensed Product” shall mean any pharmaceutical composition, dosage form or preparation, including, without limitation,
a Combination Product that contains as an active ingredient the Licensed Compound or any metabolite, prodrug, acid form, base form, ester, salt, stereoisomer, racemate, tautomer or polymorph of a Licensed Compound. 

1.23 “Major European Country” shall mean any of France, Germany, Italy, Spain or the United Kingdom. 

1.24 “Manufacture” shall mean all activities related to the manufacturing of a pharmaceutical product, or any ingredient
thereof, including but not limited to test method development and stability testing, formulation, process development, manufacturing for use in non-clinical or clinical studies, manufacturing scale-up, manufacturing Licensed Compound or Licensed
Product quality assurance/quality control development, quality control testing (including in-process release and stability testing), packaging, release of product or any component or ingredient thereof, quality assurance activities related to
manufacturing and release of product, and regulatory activities related to all of the foregoing. 
 1.25 “Marketing
Authorization” shall mean all approvals from the relevant Regulatory Authority necessary to market and sell a Licensed Product in any country (including without limitation all applicable Price Approvals even if not legally required to sell
Licensed Product in a country). 
 1.26 “Merck Know-How” shall mean the Know-How owned or controlled by Merck and/or any of
its Affiliates as of the Effective Date that was used by Merck or its Affiliates as of the Effective Date in the Development or Manufacture of Licensed Compound that is listed on Schedule B or is otherwise provided to Licensee by Merck under
this Agreement. 
 1.27 “NDA” shall mean a New Drug Application, Biologics License Application, Worldwide Marketing
Application, Marketing Application Authorization, filing pursuant to Section 510(k) of the Act, or similar application or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a
biological, pharmaceutical or diagnostic product in that country or in that group of countries. 
 1.28 “Net Sales” shall
mean the gross invoice price (not including value added taxes, sales taxes, or similar taxes) of Product sold by Licensee or its Related Parties to the first Third Party after deducting, if not previously deducted, from the amount invoiced or
received: 
 [***]. 

  
 4 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Sales or other commercial dispositions of Licensed Products between or among Related Parties
shall be excluded from the computation of Net Sales if such sales are not intended for end use. Licensed Products provided to Third Parties without charge, in connection with research and development, clinical trials, compassionate use, humanitarian
and charitable donations or indigent programs for use as samples shall be excluded from the computation of Net Sales and no payments will be payable on such dispositions. 

1.29 “PEGylated” shall mean attached to a polyethylene glycol molecule. 

1.30 “PEG-IL10” shall mean PEGylated human interleukin-10 polypeptide but not un-PEGylated human interleukin-10 polypeptide.

 1.31 “Price Approval” shall mean the approval or determination by a Regulatory Authority for the pricing or pricing
reimbursement for a pharmaceutical product. 
 1.32 “Proprietary Information” shall mean, as applicable, Know-How and all
other scientific, clinical, regulatory, marketing, financial and commercial information or data, whether communicated in writing, verbally or electronically, that is provided by one Party to the other Party in connection with this Agreement. 

1.33 “Regulatory Authority” shall mean any United States federal, state, or local government, or any foreign government, or
political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any
court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body with responsibility for granting licenses or approvals, including Marketing Authorizations, necessary for the marketing and sale of
the Licensed Product in any country. 
 1.34 “Related Party” shall mean each of Licensee, its Affiliates, and their
respective sublicensees (which term does not include distributors), as applicable. 
 1.35 “Territory” shall mean the
entire world. 
 1.36 “Third Party” shall mean an entity other than Merck and its Affiliates and Licensee and its Related
Parties. 
 1.37 “Valid Claim” shall mean a claim of an issued and unexpired patent included within the Compound Patent
Rights, that has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been disclaimed,
denied or admitted to be invalid or unenforceable through reissue or disclaimer. 

  
 5 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.38 Additional Definitions. Each of the following definitions is set forth in the
Section of this Agreement indicated below. 
  

			
	 Definition
	  	 Section

	AAA	  	13.02(a)
	Agents	  	9.01(b)
	Agreement	  	Preamble
	CFR	  	1.14
	Change of Control	  	14.01(c)
	Development Plan	  	3.02
	Development Report	  	3.03
	Effective Date	  	Preamble
	Excluded Claim	  	13.02
	FDA	  	1.13
	Force Majeure	  	14.08
	Liability	  	11.01
	LIBOR	  	7.05(e)
	Licensee Indemnified Party	  	11.02
	Merck Indemnified Party	  	11.01
	Sublicense Agreement	  	2.04
	Term	  	12.01

 ARTICLE II – LICENSE 

2.01 License Grant. Subject to the terms and conditions of this Agreement, Merck hereby grants to Licensee an exclusive (even as to
Merck and its Affiliates), royalty bearing license in the Territory in the Field, with the right to grant sublicenses as provided herein, under the Compound Patent Rights and the Merck Know-How, to Develop, make, have made, use, import, export,
Commercialize, sell, offer for sale, and market the Licensed Product in the Field in the Territory during the Term. Merck grants to Licensee a non-exclusive royalty bearing license, in the Field, in the Territory, with the right to grant sublicenses
as provided herein, to any patent rights listed in Schedule A that are not exclusively directed to the Licensed Compound, but that encompasses human interleukin-10 that is not PEGylated, which are reasonably necessary for Licensee to Develop,
make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product in the Field in the Territory during the Term. The licenses granted in this Section 2.01 may be sublicensed by Licensee to a Related
Party or to a Third Party for any country in the Territory without the consent of Merck. [***]. Any obligation of Merck to transfer tangible material set forth in Schedule B to Licensee and to provide assistance and support with such
materials will not extend beyond [***] days after the Effective Date and will only be to the extent possible by the expenditure of commercially reasonable efforts. 

  
 6 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 2.02 No Other Licenses. For a period of [***] after the Effective date, Merck will not
grant any further licenses to any Third Party under the Compound Patent Rights and the Merck Know-How, to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, or market the Licensed Compound or the Licensed Product for
acceleration or promotion of healing of wounds (including chronic wounds), the prevention or reduction of scarring, or the treatment or prevention of fibrotic disorders; in the Territory. Neither Party grants to the other Party any rights or
licenses in or to any intellectual property, whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement. 

2.03 Sublicense Agreements. Licensee shall, in each agreement under which it grants a sublicense under the license set forth in
Section 2.01 (each, a “Sublicense Agreement”), require the sublicensee to transfer to Merck, if this Agreement terminates for any reason but for termination by Licensee under Section 12.03 and to Licensee, if only such
sublicense terminates, (a) all regulatory filings and Marketing Authorizations held, possessed or controlled by such sublicensee and (b) all patent rights and Know-How controlled by such sublicensee relating to a Licensed Product or its
use, Manufacture, sale, or importation (such patent rights and Know-How shall be transferred either by assignment or by a freely sublicensable exclusive license). Licensee shall (i) use reasonable efforts to procure the performance by any
sublicensee of the terms of each such sublicense Agreement, and (ii) ensure that any sublicensee will comply with the applicable terms and conditions of this Agreement. Licensee hereby guarantees the performance of its Affiliates and
sublicensees that are sublicensed as permitted herein, and the grant of any such sublicense will not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such Affiliate or sublicensee.

 2.04 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this
Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. Each Party
shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any other jurisdiction. Upon the bankruptcy of either Party, the other Party shall further be entitled to a complete duplicate
of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to such other Party, unless the Party in bankruptcy elects to continue, and continues, to perform all
of its obligations under this Agreement. 
 ARTICLE III – DEVELOPMENT AND COMMERCIALIZATION 

3.01 Overview. As of the Effective Date, Licensee shall be solely responsible for the Development and Commercialization,
including all costs thereof, of the Licensed Product in the Field in the Territory. Licensee shall perform all of its Development activities in accordance with any IND for the Licensed Product and with all applicable laws, rules and regulations.

 3.02 Development and Commercialization Plans. Licensee shall perform, and shall ensure that its Affiliates, sublicensees, and
Third Party contractors perform, the activities described in any Development Plan for the Licensed Product in a professional manner and in compliance with, to the extent applicable, Good Laboratory Practices, Good Clinical Practices and/or Good
Manufacturing Practices and in compliance with all other applicable laws, rules, and regulations. 

  
 7 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 3.03 Development Reports. Licensee shall provide Merck with reasonably detailed
reports describing its progress with respect to its Development efforts under this Agreement (hereinafter “Development Reports”). Such Development Reports shall be furnished annually until the First Commercial Sale. Each Development Report
shall include the following information for the Licensed Product: a description of the Development work conducted during the year in reasonable detail, including clinical studies, formulation work, manufacturing work, and other testing work and
regulatory activity; timelines for such work; and key decision gates and milestones anticipated for such work. All Development Reports created by Licensee shall be deemed the Proprietary Information of Licensee and are subject to the confidentiality
obligations of Article IX. 
 3.04 Commercialization. Licensee shall promptly give Merck written notice that it has filed an NDA for
the Licensed Product and at that time shall further provide Merck with the anticipated date of First Commercial Sale for the Licensed Product in the country of filing. Licensee shall promptly provide Merck with notice of any Marketing Authorization
of Licensed Product. 
 3.05 Notice and Negotiation. Licensee shall notify Merck, in advance and in writing, if at any time during
the Term, Licensee intends to offer a license of any kind or to assign, transfer or otherwise convey rights to research, develop, commercialize, manufacture, have manufactured, use, import, export, sell, and/or offer for sale the Licensee Product.
For clarity, (i) an agreement with a contractor, contract research organization, contract manufacturer or other Third Party, under which such Third Party performs contract services on behalf of Licensee or its Affiliates, shall not be subject
to this Section 3.04, and (ii) this Section 3.04 shall not apply to a Change of Control. 
 ARTICLE IV – REGULATORY

 4.01 Materials and Regulatory Filings Transfer. 

(a) Following the Effective Date of this Agreement, but not before the payment of the consideration under Section 7.01 by Licensee to
Merck, Merck shall transfer to Licensee, in a mutually agreed manner, the [***] reasonably within the possession and control of Merck and necessary for Licensee to make, use and sell the Licensed Product. Any obligation of Merck to transfer such
tangible material to Licensee and to provide assistance and support with such materials will not extend beyond [***] days after the Effective Date and will only be to the extent possible by the expenditure of commercially reasonable efforts. 

(b) Licensee or its Affiliates shall hold all Marketing Authorizations for Licensed Product in the Territory in the Field. 

  
 8 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (c) Licensee shall oversee, monitor and coordinate all regulatory actions, communications and
filings with, and submissions to, the FDA and other regulatory authorities in the Field in the Territory with respect to Licensed Product. 

(d) Licensee shall be solely responsible for interfacing, corresponding and meeting with the FDA and other regulatory authorities throughout
the Territory with respect to Licensed Product. 
 (e) Licensee shall provide to Merck a [***] that contains the status of Marketing
Authorizations for the Licensed Product in the Territory. 
 (f) In the event that any Regulatory Authority (a) threatens or initiates
any action to remove a Licensed Product from the market in any country in the Field in the Territory or (b) requires Licensee, its Affiliates, or its sublicensees to distribute a “Dear Doctor” letter or its equivalent regarding use of
Licensed Product in the Field, Licensee shall notify Merck of such event within one (1) business day after Licensee becomes aware of the action, threat, or requirement (as applicable). Licensee shall consult with Merck prior to initiating a
recall or withdrawal of Licensed Product in the U.S., Japan, or a Major European Country; provided, however, that the final decision as to whether to recall or withdraw a Licensed Product in the Territory shall be made by Licensee in its sole
discretion. Licensee shall be responsible, at its sole expense, for conducting any recalls or taking such other necessary remedial action. 

(g) [***]. 
 ARTICLE V –
DILIGENCE 
 5.01 Generally. Licensee shall use Diligent Efforts to Develop and Commercialize the Licensed Product in the Field
in the Territory. 
 5.02 Failure. Any failure by Licensee to comply with the obligations set forth in this Article V in
significant and material respects shall be subject to Article XIII, and any other available remedies at law or in equity. 

ARTICLE VI – MANUFACTURING 

6.01 Manufacturing Responsibility. Licensee will be responsible for the manufacturing of the Licensed Compound and Licensed Product for
use by Licensee, its Affiliates, and its sublicensees in the Field in the Territory. 
 ARTICLE VII – PAYMENTS; ROYALTIES AND REPORTS

 7.01 Consideration for License. In consideration for the license granted to Licensee hereunder, Licensee shall pay to Merck a
non-refundable, non-creditable payment of [***] U.S. dollars ($[***]), which shall be due within [***] days of the Effective Date. 

  
 9 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 7.02 Milestone Payments. Subject to the terms and conditions of this Agreement and in
further consideration for the license granted herein, Licensee shall make each of the following one-time, non-refundable, non-creditable milestone payments to Merck based on attainment of the Development, regulatory and commercial milestones
indicated below: 
  

					
	 Milestone
	  	Payment	 
	 [***]
	  	 	[	***] 

 Licensee shall promptly notify Merck in writing after the achievement of each such milestone event giving rise to a payment
obligation under this Section and Licensee shall pay Merck the indicated amount no later than [***] days after the achievement of each milestone event giving rise to a payment obligation under this Section 7.02. 

7.03 Royalties. 
 (a)
Royalty Rates. Subject to the terms and conditions of this Agreement, Licensee shall pay to Merck royalties on Net Sales of Licensed Product on a country-by-country basis in an amount equal to: 

[***]. 
 (b) Term of Royalty
Obligation. Royalties on the Licensed Product shall commence upon the First Commercial Sale of a Licensed Product in a particular country in the Territory and will continue on a product-by-product, country-by-country basis until the later of (i)
the expiration of the last to expire Valid Claim of the Compound Patent Rights covering a Licensed Product in such country or (ii) the tenth (10th) anniversary of the date of the First Commercial Sale of the Licensed Product in such country. 

7.04 Reports; Payment of Royalty; Payment Exchange Rate and Currency Conversions. 

(a) Royalties Paid Quarterly. Within [***] calendar days following the end of each Calendar Quarter, following the First Commercial Sale
of a Licensed Product, Licensee shall furnish to Merck a written report for the Calendar Quarter showing the Net Sales of Licensed Product sold by Licensee, its Affiliates and its sublicensees in the Territory during such Calendar Quarter and the
royalties payable under this Agreement for such Calendar Quarter. Such written report shall include the gross sales of Licensed Product on a country-by-country basis, an itemized calculation of any deductions taken from such gross sales to arrive at
Net Sales for the applicable Calendar Quarter and the calculation of the amount of royalty payment due on such Net Sales. Simultaneously with the submission of the written report, Licensee shall pay to Merck, for the account of Licensee or the
applicable Affiliate or sublicensee, as the case may be, a sum equal to the aggregate royalty due for such Calendar Quarter calculated in accordance with this Agreement. 

  
 10 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) Method of Payment. All payments to be made by Licensee to Merck under this
Agreement shall be paid by bank wire transfer in immediately available funds to such bank account as is designated in writing by Merck from time to time. Royalty payments shall be made in United States dollars to the extent that free conversions to
United States dollars is permitted. The rate of exchange to be used in any such conversion from the currency in the country where such Net Sales are made shall be the rate of exchange used by Licensee for reporting such sales for United States
financial statement purposes. If, due to restrictions or prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the Parties shall consult with a view to finding a prompt and acceptable solution, and
Licensee will make such payments in any manner as Merck may lawfully direct; provided that Licensee shall not be obligated to incur any additional out-of-pocket expenses in connection with such payments. Notwithstanding the foregoing, if royalties
in any country cannot be remitted to Merck for any reason within [***] months after the end of the Calendar Quarter during which they are earned, then Licensee shall be obligated to deposit the royalties in a bank account in such country in the name
of Merck. 
 7.05 Maintenance of Records; Audits. 

(a) Record Keeping by Licensee. Licensee and its Affiliates shall keep complete and accurate records in sufficient detail to enable the
royalties payable hereunder to be determined. Upon [***] days prior written notice from Merck, Licensee shall permit an independent certified public accounting firm of nationally recognized standing selected by Merck and reasonably acceptable to
Licensee, at Merck’s expense, to have access during normal business hours to examine the pertinent books and records of Licensee, its Affiliates and/or sublicensees as may be reasonably necessary to verify the accuracy of the royalty reports
hereunder. [***]. Licensee may designate competitively sensitive information that such auditor may not disclose to Merck, provided, however, that such designation shall not encompass the auditor’s conclusions. The accounting firm shall disclose
to Merck only whether the royalty reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Merck. All such accounting firms shall sign a confidentiality agreement (in form and
substance reasonably acceptable to Licensee) as to any of Licensee’s or its Affiliate‘s confidential information that such accounting firms are provided, or to which they have access, while conducting any audit pursuant to this
Section 7.05(a). 
 (b) Underpayments/Overpayments. If such accounting firm correctly concludes that additional royalties were
owed during such period, Licensee shall pay such additional royalties within [***] days of the date Merck delivers to Licensee such accounting firm’s written report so correctly concluding. If such underpayment exceeds [***] dollars ($[***])
and [***] percent ([***]%) of the sums correctly due Merck then the fees charged by such accounting firm for the work associated with the underpayment audit shall be paid by Licensee. [***]. 

(c) Record Keeping by Sublicensee. Licensee shall include in each sublicense granted by it pursuant to this Agreement a provision
requiring the sublicensee to make reports to Licensee, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by an independent accountant to the same extent required of Licensee under this
Agreement. 

  
 11 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (d) Confidentiality. Merck shall treat all financial information subject to review
under this Section 7.05, or under any sublicense agreement, in accordance with the confidentiality provisions of Article IX of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with
Licensee obligating it to retain all such financial information in confidence pursuant to such confidentiality agreement. 
 (e) Late
Payments. Any amount owed by Licensee to Merck under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the rate of [***] as of the due date. 

ARTICLE VIII – PATENTS 

8.01 Prosecution and Maintenance of Patents. Licensee shall prosecute and maintain in the Territory, through outside counsel, the
patents and patent applications that are set forth in Schedule C. Following the [***] milestone referred to in Section 7.02, however, [***]. Each party shall bear its own costs related to such prosecution and maintenance and shall manage
any administrative challenge to [***], including any interference, post-grant review, inter partes review, derivation proceeding, opposition, reexamination, reissue or similar administrative proceeding. Licensee shall manage any such
interference, post-grant review, inter partes review, derivation proceeding, opposition, reexamination, reissue or similar administrative proceeding through outside counsel. [***]. Licensee shall keep Merck advised of such prosecution and
maintenance of patents and applications set forth in Schedule C and upon the written request of Merck, will provide advance copies of any substantive papers to be filed in connection with such prosecution and maintenance, including such
applications, amendments thereto and other related correspondence to and from patent offices. 
 8.02 All Inventions that are created during
the Term of the Agreement jointly by employees, Affiliates, agents, independent contractors or consultants of Licensee and employees, Affiliates, agents, independent contractors or consultants of Merck that claim or cover the Licensed Product or
Licensed Compound shall be owned jointly by Merck and Licensee (“Joint Patent Rights”). Merck hereby grants to Licensee an exclusive (even as to Merck and its Affiliates), license, in the Field in the Territory, with the right to grant
sublicenses under the Joint Patent Rights to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Compound and the Licensed Product. Licensee agrees to prosecute and maintain in the Territory,
through outside counsel, the Joint Patent Rights. Following the [***] milestone referred to in Section 7.02, however, at the request of Licensee, [***]. Licensee also agrees to manage, through outside counsel, any administrative challenge to
the Joint Patent Rights including any interference, post-grant review, inter partes review, derivation proceeding, opposition, reexamination, reissue or similar administrative proceeding. Licensee may use outside counsel of its choice for
matters in connection with the Joint Patent Rights. 

  
 12 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 8.03 Option of Licensee to Prosecute and Maintain Patents. Each Party shall give [***]
days ([***]) advanced written notice to the other Party (the “Notified Party”) of any desire to cease prosecution and/or maintenance of the patents and patent applications set forth in Schedule C or Schedule D
including a desire to not maintain pendency, in each country, of at least one member of the family of any such patent or application. If the Notified Party provides written notice, within the [***] days, of a desire to continue prosecution or
maintenance of the patents and patent applications on which the other Party desires to cease prosecution and/or maintenance, then such other Party shall permit the Notified Party to do so at the expense of the Notified Party. 

8.04 Enforcement. 
 (a)
Licensee Enforcement. In the event that either Licensee or Merck becomes aware of any alleged or threatened commercially material infringement in a country in the Territory of any issued patent within the Compound Patent Rights or Joint
Patent Rights, it will notify the other Party in writing to that effect. Licensee shall have the first right (but not the obligation) to enforce any such Compound Patent Right or Joint Patent Right against any such infringer or alleged infringer, at
its own expense, and control, and litigate and settle, such suit as set forth herein. Merck shall reasonably cooperate in any such suit at Licensee’s expense; and where necessary, Merck shall join in, or be named as a necessary party to, such
suit. Licensee shall not enter into any settlement of any claim described in this Section 8.04(a) that, in the reasonable judgment of Merck would violate any law or regulation, admits to the invalidity or unenforceability of the Compound Patent
Rights or Joint Patent Rights, incurs any financial liability on the part of Merck, requires an admission of liability, wrongdoing, or fault on the party of Merck, without Merck’s prior written consent (in each case, such consent not to be
unreasonably withheld). Merck shall have the right, prior to commencement of the trial, suit or action brought by Licensee, to join any such suit or action, and in such event shall pay one-half of the costs of such suit or action. 

(b) Merck Enforcement. If Licensee does not obtain a discontinuance of a commercially material infringement or alleged commercially
material infringement of a Compound Patent Right or Joint Patent Right in a particular country, or bring suit against the Third Party infringer or alleged Third Party infringer, in each case within [***] ([***]) months of receiving notice thereof,
then Merck shall have the right to enforce any such patent and control, and litigate and/or settle such suit as set forth herein. Licensee will reasonably cooperate with Merck in any such suit at Merck’s expense; and where necessary, Licensee
shall join in, or be named as a necessary party to, such suit. Merck shall not enter into any settlement of any claim described in this Section 8.04(b) that admits to the invalidity or unenforceability of the Compound Patent Rights or Joint
Patent Rights, incurs any financial liability on the part of Licensee, requires an admission of liability, wrongdoing, or fault on the party of Licensee, without Licensee’s prior written consent (in each case, such consent not to be
unreasonably withheld). Licensee shall have the right, prior to commencement of the trial, suit or action brought by Merck, to join any such suit or action, and in such event shall pay one-half of the costs of such suit or action. 

  
 13 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (c) Recovery. Any recovery or damages derived from any suit brought under
Section 8.04 (“Recovery”) shall be shared as follows: (i) the amount of such Recovery shall be used first to reimburse each of Merck and Licensee for its documented out-of-pocket legal expenses relating to the suit, and then
(ii) any remaining amounts to be shared by the Parties as follows: 
 [***] 

8.05 Infringement and Third Party Licenses. 

(a) Course of Action. In the event that Licensee’s, its Affiliates” or its sublicensees” making, having made, importing,
exporting, using, Manufacturing, having Manufactured Licensed Compound or distributing, marketing, promoting, offering for sale or selling Licensed Product infringes, will infringe or is alleged by a Third Party to infringe, a claim of a patent that
specifically covers the Licensed Compound or its Manufacture, the Party becoming aware of same shall promptly notify the other. Licensee shall determine a course of action that may include: (i) modification of the Licensed Product or its use
and Manufacture so as to be non-infringing; or (ii) obtaining a license or assignment from said Third Party. 
 (b) Licensee Right to
Negotiate. In the event Licensee or a Related Party obtains any license(s) or immunity from suit under the intellectual property of a Third Party in connection with the manufacture, distribution, use, sale, offer for sale or import of a Licensed
Product, and if the total royalty burden exceeds [***]% of annual Net Sales, then for every [***]% above [***]%, Licensee will be entitled to reduce the royalty payable to Merck by [***]% up to a maximum of [***]% in total. In any event,
Merck’s applicable royalty will never be reduced by more that [***]%. 
 (c) If Licensee obtains additional rights to Develop, make,
have made, use, import, export, Commercialize, sell, offer for sale, and market subject matter relating to IL-10, and if Merck, alone, deems such rights to be sufficient and obtained in a manner not prejudicial to Merck’s rights under existing
agreements, then Merck and Licensee will agree to execute an amendment to this Agreement to define Field, under Section 1.11 of this Agreement, to include acceleration or promotion of healing of wounds (including chronic wounds), the prevention
or reduction of scarring, or the treatment or prevention of fibrotic disorders. In the event that Licensee obtains such rights, Licensee agrees to cooperate fully with Merck in providing sufficient evidence to Merck of such rights and the manner
obtained. 
 8.06 Third Party Infringement Suit. In the event that a Third Party sues Licensee alleging that Licensee’s, its
Affiliates” or its sublicensees” making, having made, importing, exporting, using, manufacturing, having manufactured Licensed Compound or distributing, marketing, promoting, offering for sale or selling Licensed Product infringes or will
infringe a claim of a patent that specifically covers the Licensed Compound or its manufacture, then Licensee may elect to defend such suit and, during the period in which such suit is pending, notwithstanding Licensee’s obligation to indemnify
Merck under Section 11.01 herein, [***]. 

  
 14 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 8.07 Abandonment. Merck shall promptly give notice to Licensee of the grant lapse,
revocation, surrender, invalidation or abandonment of any Compound Patent Rights licensed to Licensee for which Merck is responsible for the prosecution and maintenance under this Agreement. 

ARTICLE IX – CONFIDENTIALITY AND PUBLICATION 

9.01 Confidentiality. 

(a) Nondisclosure Obligation. Each of Merck and Licensee shall use any Proprietary Information received by it from the other Party only
in accordance with this Agreement and shall not disclose to any Third Party any such Proprietary Information without the prior written consent of the other Party. The foregoing obligations shall survive the expiration or termination of this
Agreement for a period of [***] years. These obligations shall not apply to Proprietary Information that: 
 (i) is known by the receiving
Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s written records; 

(ii) is at the time of disclosure, or thereafter becomes, published or otherwise part of the public domain without breach of this Agreement by
the receiving Party; 
 (iii) is subsequently disclosed to the receiving Party by a Third Party who has the right to make such disclosure,
as documented by the receiving Party’s written records; 
 (iv) is independently developed by the receiving Party or its Affiliates and
without the aid, use or application of any of the disclosing Party’s Proprietary Information, and such independent development can be documented by the receiving Party’s written records; 

(v) is disclosed to any institutional review board of any entity conducting clinical trials with Licensed Product or to any governmental or
other regulatory agencies in order to obtain patents or to gain approval to conduct clinical trials or to market Licensed Product, provided that such disclosure may be made only to the extent reasonably necessary to obtain such patents or
authorizations; or 
 (vi) is required to be disclosed by law, regulation, rule, act or order of any governmental authority or agency to be
disclosed, provided that notice is promptly delivered to the other Party in order to provide an opportunity to seek a protective order or other similar order with respect to such Proprietary Information and thereafter the receiving Party discloses
to the requesting entity only the minimum information required to be disclosed in order to comply with the request, whether or not a protective order or other similar order is obtained by the other Party. 

  
 15 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) Disclosure to Agents. Notwithstanding the provisions of Section 9.01(a) and
subject to the other terms of this Agreement, each of Licensee and Merck shall have the right to disclose Proprietary Information to their respective sublicensees, agents, consultants, Affiliates or other Third Parties (collectively
“Agents”) in accordance with this Section 9.01(b). Such disclosure shall be limited only to those Agents directly involved in the management and decision-making of Licensee and/or the Development, Manufacturing, marketing or promotion
of Licensed Compound or Licensed Product (or for such Agents to determine their interest in performing such activities) in accordance with this Agreement. Any such Agents must already be bound or agree in writing to be bound by confidentiality and
non-use obligations essentially the same as those contained in this Agreement. 
 9.02 Return of Confidential Information. Upon
termination of this Agreement, the receiving Party will return or destroy all documents, and copies thereof, including those in the possession of the receiving Party’s Agents pursuant to Section 9.01(b), containing the disclosing
Party‘s Proprietary Information at any time upon the written request of the disclosing Party. However, the receiving Party may retain one (1) copy of such documents in a secure location solely for the purposes of (i) determining its
obligations hereunder, (ii) complying with any applicable regulatory requirements, or (iii) defending against any product liability claim. 

9.03 Breach of Confidentiality. The Parties agree that the disclosure of the Disclosing Party’s Proprietary Information in
violation of this Agreement may cause the Disclosing Party irreparable harm and that any breach or threatened breach of this Agreement by the Receiving Party entitles disclosing Party to seek injunctive relief, in addition to any other legal or
equitable remedies available to it, in any court of competent jurisdiction. For clarity, such disputes shall not be subject to Article XIII. 

9.04 No Publicity. A Party may not use the name of the other Party in any publicity or advertising and may not issue a press release or
otherwise publicize or disclose any information related to the existence of this Agreement or the terms or conditions herein, except (i) on the advice of its counsel as required by law (e.g., any Securities and Exchange Commission filings and
disclosures) and provided the Party who will be disclosing such information has consulted with the other Party to the extent feasible prior to such disclosure with respect to the substance of the disclosure; and (ii) that any press release with
respect to the existence of this Agreement or the terms or conditions herein shall be subject to each party’s prior review and approval; and, such approval shall not be unreasonably withheld. Licensee shall provide Merck with reasonable advance
written notice of any press release or other public disclosure of the results of any of its work on Licensed Product under this Agreement. 

9.05 Terms of Agreement. Neither Party nor its Affiliates shall disclose any terms or conditions of this Agreement to any Third Party
without the prior consent of the other Party, except as follows: A Party and its Affiliates may disclose the terms or conditions of this Agreement (but not any other Proprietary Information, which may be disclosed only as described elsewhere in this
Article IX), (a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary, provided that such advisors are subject to confidentiality with regard to such information under an agreement or
ethical obligation; (b) to a 

  
 16 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Third Party in connection with (i) a financing (or proposed financing) or an equity investment (or proposed investment) in such Party or its Affiliates, including to its shareholders and
prospective shareholders, (ii) a merger, consolidation or similar transaction by such Party or its Affiliates, (iii) the sale of all or substantially all of the assets of such Party or its Affiliates, or (iv) in connection with a
Securitization, provided that such Third Party executes a non-use and non-disclosure agreement and observes the same obligations of confidentiality as such Party owes under this Agreement with respect to Proprietary Information of the other Party;
(c) to the United States Securities and Exchange Commission or any other securities exchange or governmental entity, including as required to make an initial or subsequent public offering, or (d) as otherwise required by law or regulation,
provided that in the case of (c) and (d) the disclosing Party shall (x) if practicable, provide the other Party with reasonable advance notice of and an opportunity to comment on any such required disclosure, (y) if requested by
such other Party, seek, or cooperate with such Party’s efforts to obtain, confidential treatment or a protective order with respect to any such disclosure to the extent available at such other Party’s expense, and (z) use good faith
efforts to incorporate the comments of such other Party in any such disclosure or request for confidential treatment or protective order. 

ARTICLE X – REPRESENTATIONS AND WARRANTIES 

10.01 Representations and Warranties of Each Party. Each of Merck and Licensee hereby represents, warrants and covenants to the other
Party hereto as follows: 
 (a) it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of
its incorporation; 
 (b) the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite
corporate action; 
 (c) it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

(d) the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions herein does not
and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or
affecting it or its property; (ii) the provisions of its corporate charter or other operative documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of
its property is bound; 
 (e) except for the governmental and Marketing Authorizations required to market the Licensed Product in the
Territory, the execution, delivery and performance of this Agreement by such Party does not require the consent, approval or authorization of, or notice, declaration, filing or registration with, any governmental or Regulatory Authority and the
execution, delivery or performance of this Agreement will not violate any law, rule or regulation applicable to such Party; 

  
 17 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (f) this Agreement has been duly authorized, executed and delivered and constitutes such
Party’s legal, valid and binding obligation enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting
creditors” rights and to the availability of particular remedies under general equity principles; and 
 (g) it shall comply with all
applicable material laws and regulations relating to its activities under this Agreement. 
 10.02 Merck Representation. Merck hereby
represents, warrants and covenants to Licensee as follows: 
 Schedule A contains a complete and accurate listing of the Compound
Patent Rights as of the Effective Date [***]; 
 10.03 Licensee’s Representations. Licensee hereby represents, warrants and
covenants to Merck as follows: 
 (a) during the Term of this Agreement it will not use in any capacity, in connection with any services to
be performed under this Agreement, any individual who has been debarred pursuant to the United States Food, Drug and Cosmetic Act; 
 (b) it
has or will obtain, during the term of this Agreement, the capacity and resources to Develop and Commercialize Licensed Product and to Manufacture Licensed Compound. 

10.04 No Inconsistent Agreements. Neither Party has in effect, and after the Effective Date neither Party shall enter into, any oral or
written agreement or arrangement that would be inconsistent with its obligations under this Agreement. 
 10.05 Representation by Legal
Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting of this Agreement. In interpreting and applying the terms and
provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions. 

10.06 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE X, THE LICENSED COMPOUND, LICENSED PRODUCT, COMPOUND PATENT RIGHTS AND
MERCK KNOW-HOW ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE
OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 

  
 18 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.07 No Warranty. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
PARTY HERETO MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. IN PARTICULAR, BUT WITHOUT LIMITATION, MERCK MAKES NO REPRESENTATION AND EXTENDS NO WARRANTY CONCERNING WHETHER THE LICENSED COMPOUND OR LICENSED
PRODUCT IS FIT FOR ANY PARTICULAR PURPOSE OR SAFE FOR HUMAN CONSUMPTION. 
 ARTICLE XI – INDEMNIFICATION AND LIMITATION ON LIABILITY

 11.01 Indemnification by Licensee. Licensee shall indemnify, defend and hold harmless Merck and its Affiliates, and each of
its and their respective employees, officers, directors and agents (each, a “Merck Indemnified Party”) from and against any and all liability, loss, damage, cost, and expense (including reasonable attorneys” fees), subject to
the limitations in Section 11.05 (collectively, a “Liability”) that a Merck Indemnified Party may incur, suffer or be required to pay resulting from or arising out of (i) the development, Manufacture, promotion, distribution,
use, marketing, sale or other disposition of the and/or Licensed Product by Licensee, its Affiliates or sublicensees, (ii) any breach by Licensee of any of its representations, warranties and covenants contained in Sections 10.01 and 10.03
herein, and (iii) the negligence and/or willful misconduct of Licensee, its Affiliates or sublicensees. Notwithstanding the foregoing, Licensee shall have no obligation under this Agreement to indemnify, defend or hold harmless any Merck
Indemnified Party with respect to any Liabilities that result from the gross negligence or willful misconduct of Merck, Merck Indemnified Party or any of their respective employees, officers, directors or agents or that result from Merck’s
breach of its obligations under this Agreement. 
 11.02 Indemnification by Merck. [***]. 

11.03 Conditions to Indemnification. The obligations of the indemnifying Party under Sections 11.01 and 11.02 are conditioned upon the
delivery of written notice to the indemnifying Party of any potential Liability promptly after the indemnified Party becomes aware of such potential Liability. The indemnifying Party shall have the right to assume the defense of any suit or claim
related to the Liability if it has assumed responsibility for the suit or claim in writing; however, if in the reasonable judgment of the indemnified Party, such suit or claim involves an issue or matter that could have a materially adverse effect
on the business operations or assets of the indemnified Party, the indemnified Party may retain control of the defense or settlement thereof by providing written notice of such effect to the indemnifying Party, but in no event shall such action or
notice be construed as a waiver of any indemnification rights that the indemnified Party may have at law or in equity. If the indemnifying Party defends the suit or claim, the indemnified Party may participate in (but not control) the defense
thereof at its sole cost and expense. The foregoing notwithstanding, the Parties acknowledge and agree that failure of the indemnified Party to promptly notify the indemnifying Party of a potential Liability shall not constitute a waiver of, or
result in the loss of, such Party’s right to indemnification under Section 11.01 or 11.02, as appropriate, except to the extent that the indemnifying Party’s rights, and/or its ability to defend against such Liability, are materially
prejudiced by such failure to notify. 

  
 19 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 11.04 Settlements. Neither Party may settle a claim or action related to a Liability
without the consent of the other Party, and such consent shall not be unreasonably withheld, if such settlement would impose any monetary obligation on the other Party or require the other Party to submit to an injunction or otherwise limit the
other Party‘s rights under this Agreement. Any payment made by a Party to settle any such claim or action shall be at its own cost and expense. 

11.05 [***]. 
 11.06
Insurance. At such time as Licensee or any of its sublicensees begins any Clinical Trial relating to Licensed Product, Licensee shall, at its own expense, procure and maintain policies of comprehensive general liability
insurance (including without limitation product liability insurance) in the amount of [***] Dollars ($[***]). All such policies shall name Merck as an additional insured, and insurers will waive all rights of subrogation against
Merck. Upon Merck’s request, Licensee will promptly provide for itself and its sublicensees copies of certificates of insurance evidencing such coverages. Licensee shall notify Merck not less than [***] days in advance of
any material change or cancellation of any policy. Licensee shall continue to maintain such insurance in effect after the expiration or termination of this Agreement during any period in which Licensee or its sublicensee continues to
make, have made, use, sell, offer to sell or import Licensed Product. If any insurance is on a claims made basis, Licensee will maintain such insurance for a period of not less than [***] years after it has ceased all commercial sale,
distribution or use of any Product. 
 ARTICLE XII – TERM AND TERMINATION 

12.01 Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated earlier by mutual written
agreement of the Parties or pursuant to Sections 12.02 or 12.03 below, the Term of this Agreement shall continue in effect on a country-by-country and product-by-product basis until the expiration of Licensee‘s obligation to pay royalties under
Article VII herein (the “Term”). Upon expiration of this Agreement in its entirety, Licensee’s license pursuant to Section 2.01 shall become a fully paid-up, perpetual license. 

12.02 Termination by Licensee. 

(a) Licensee’’s Right to Terminate. Notwithstanding anything contained herein to the contrary, Licensee shall have the
unilateral right to terminate this Agreement in its entirety without cause at any time by giving [***] days advance written notice to Merck. In the event of such termination, the rights and obligations hereunder shall terminate; provided, however,
that any payment obligations due and owing as of the termination date shall continue. 
 (b) Effect of Termination. Notwithstanding
anything contained herein to the contrary, following any termination of this Agreement in its entirety under Section 12.02(a), all rights and licenses granted to Licensee hereunder shall revert back to Merck pursuant to Section 12.05. 

  
 20 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 12.03 Termination for Cause. 

(a) Termination for Cause. This Agreement may be terminated, in its entirety by written notice by either Party at any time during the
Term of this Agreement: 
 (i) upon or after the breach of any material provision of this Agreement if the breaching Party has not cured
such breach within [***] days following receipt of written notice from the non-breaching Party requesting cure of the breach or, if such breach is not susceptible of cure within such sixty [***] day period, the breaching Party has not taken
appropriate steps to commence such cure during such [***]-day period and continued to diligently pursue such cure in a manner reasonably assuring such cure within a reasonable period of time thereafter (not to exceed [***] days). Any right to
terminate under this Section 12.03(a) shall be stayed and the cure period tolled in the event that, during any cure period, the Party alleged to have been in material breach shall have initiated dispute resolution in accordance with Article
XIII with respect to the alleged breach, which stay and tolling shall last so long as the allegedly breaching Party diligently and in good faith cooperates in the prompt resolution of such dispute resolution proceedings; or 

(ii) upon the filing or institution of bankruptcy wherein, in the case of filing or institution of bankruptcy of the Licensee, the Licensee
fails to use Diligent Efforts to Develop and Commercialize the Licensed Product in the Field in the Territory, reorganization wherein, in the case of reorganization of the Licensee, the Licensee fails to use Diligent Efforts to Develop and
Commercialize the Licensed Product in the Field in the Territory, liquidation or receivership proceedings by or against the other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party, or
in the event a receiver or custodian is appointed for such Party‘s business, or if a substantial portion of such Party‘s business is subject to attachment or similar process; provided, however, that in the case of any involuntary
bankruptcy proceeding, such right to terminate shall only become effective if the proceeding is not dismissed within [***] days after the filing thereof. 

(b) Effect of Termination for Cause on License. 

(i) Termination by Licensee for Cause. In the event this Agreement is properly terminated by Licensee under Section 12.03(a),
Licensee’s license pursuant to Section 2.01 shall become a fully paid-up, perpetual license; and, subject, however, to the provisions of Section 12.04, Licensee shall owe no further payments to Merck pursuant to Article VII or otherwise under
this Agreement. 
 (ii) Termination by Merck for Cause. In the event this Agreement is terminated by Merck under Section 5.02, 12.03
and/or 14.01(b), the rights and license granted to Licensee under Section 2.01 of this Agreement shall terminate and all rights to the Licensed Compound and Licensed Product shall revert to Merck pursuant to Section 12.05. 

12.04 Effect of Termination Generally. Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing prior to such expiration or termination. Any expiration or early termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to termination,
including the obligation to pay royalties for Licensed Product sold prior to such termination. 
 12.05 Licensed Product Reversion.
[***]. 

  
 21 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE XIII – DISPUTE RESOLUTION 

13.01 Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to
this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between
themselves. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within [***] days after such notice appropriate representatives of the Parties shall meet for attempted
resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said [***] days, either Party may refer the matter by written notice to the other to the appropriate [***], or his
designee, and the Chief Executive Officer of Licensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within [***] days of such written notice, either Party may initiate
arbitration proceedings in accordance with the provisions of this Article XIII. 
 13.02 Arbitration. All disputes arising out of or
relating to this Agreement, or the rights or obligations of the Parties hereunder, or relating in any way to the relationship between the Parties with respect to the Licensed Compound or Licensed Product, shall be finally and exclusively settled by
arbitration by a panel of [***] arbitrators, provided such dispute is not an “Excluded Claim”. As used in this Section, the phrase “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) the validity or
infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

(a) The arbitration proceeding shall be conducted under the [***] with such proceedings to be held in [***]. In all cases, the arbitration
proceedings shall be conducted in the English language, and all documents that are submitted in the proceeding shall be in the English language. Judgment upon the award rendered by arbitration may be issued and enforced by any court having competent
jurisdiction. 
 (b) If a Party intends to begin an arbitration to resolve a dispute, such Party shall provide written notice to the other
Party, informing the other Party of such intention and any statement of claim required under the applicable arbitration rules (as determined in accordance with Section 13.02(a)). Within [***] business days after its receipt of such notice, the
other Party shall, by written notice to the Party initiating arbitration, add any additional issues to be resolved that would be considered mandatory counterclaims under [***] law. For clarity, the resolution of any disputes regarding such
counterclaims shall be conducted in the same proceedings as the initial claims. 
 (c) [***]. 

(i) All of the arbitrators shall have significant legal or business experience in pharmaceutical licensing matters. The arbitrators shall not
be employees, directors or shareholders of either Party or any of their Affiliates. 

  
 22 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (ii) Each Party shall have the right to be represented by counsel throughout the arbitration
proceedings. 
 (iii) To the extent possible, the arbitration hearings and award will be maintained in confidence. 

(iv) In any arbitration pursuant to this Agreement, the award or decision shall be rendered by a majority of the members of the panel provided
for herein, with each member having one (1) vote. The arbitrators shall render a written decision with their resolution of the dispute that shall set forth in reasonable detail the facts of the dispute and the reasons for their decision. The
decision of the arbitrators shall be final and non-appealable and binding on the Parties. 
 13.03 Injunctive Relief. By agreeing to
arbitration, the Parties do not intend to deprive any competent court of such court’s jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award
or judgment. Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court, the court of arbitration shall have full authority to grant provisional remedies and to award damages
for failure of any Party to respect the court of arbitration’s order to that effect. 
 13.04 Expenses of Arbitration and Expert
Determination. Each Party shall bear its own attorneys” fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators; provided, however, that the arbitrators
shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees and
expenses, photocopy charges and travel expenses). Absent the filing of an application to correct or vacate the arbitration award as permitted by applicable law, each Party shall fully perform and satisfy the arbitration award within [***] days of
the service of the award. 
 ARTICLE XIV – MISCELLANEOUS 

14.01 Assignment/Change of Control.  

(a) Assignment. Neither this Agreement nor any or all of the rights and obligations of a Party hereunder may be assigned, delegated,
sold, transferred, sublicensed (except as otherwise provided herein) or otherwise disposed of, by operation of law or otherwise, to any Third Party without the prior written consent of the other Party, and any attempted assignment, delegation, sale,
transfer, prohibited sublicense or other disposition, by operation of law or otherwise, of this Agreement or of any rights or obligations hereunder contrary to this Section 14.01 shall be a material breach of this Agreement by the attempting
Party, and shall be void and without force or effect; provided, however, that either Party may, without such consent of such Party, assign the Agreement and its rights and obligations hereunder to an Affiliate or in connection with the transfer or
sale of all or substantially all of its assets related to the division or the subject business, or in the event of its merger or consolidation or change in control or similar transaction. This Agreement shall be binding upon, and inure to the
benefit of, each Party, its Affiliates, and its permitted successors and assigns. Each Party shall be responsible for the compliance by its Affiliates with the terms and conditions of this Agreement. 

  
 23 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) Change of Control at Licensee. In the event that any Change of Control (as defined
below) causes Licensee’s rights and obligations hereunder to pass to any Third Party, such Third Party shall, within [***] days after the effective date of such Change of Control, notify Merck of its intentions with regard to the Development
and Commercialization of the Licensed Product under this Agreement. If the Third Party succeeding to Licensee’s rights and obligations under this Agreement decides it will not continue the Development and/or Commercialization of the Licensed
Product, then Merck shall have the right to terminate this Agreement upon [***] days written notice to Licensee, without any opportunity to cure. If the Third Party succeeding to Licensee’s rights and obligations under this Agreement decides to
continue the Development and Commercialization of the Licensed Product, then all of the rights and obligations of Licensee under this Agreement shall inure to such Third Party. 

(c) Definition of Change of Control. As used in this Section 14.01 the term “Change of Control” shall mean (i) any
merger, reorganization, consolidation or combination in which a Party to this Agreement is not the surviving corporation, or (ii) any “person” (within the meaning of Sections 13(d) and 14 (d)(2) of the Securities Exchange Act of
1934), excluding Licensee and its Affiliates, is or becomes the beneficial owner, directly or indirectly, of securities of the Party representing 50% or more of either (a) the then-outstanding shares of common stock of the Party or its parent
corporation, or (b) the combined voting power of the Party’s then-outstanding voting securities; or (iii) if individuals who as of the Effective Date constitute the Board of Directors of the Party or its parent corporation (the
“Incumbent Board”) cease for any reason to constitute at least a majority of such Board of Directors; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by
the Party’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose,
any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on
behalf of a person other than the Incumbent Board; or (iv) approval by the shareholders of a Party of a complete liquidation or the complete dissolution of such Party. 

14.02 Governing Law. This Agreement shall be governed, interpreted and construed in accordance with the laws of the State of New York,
without giving effect to its conflict of law principles. Subject to the terms of this Agreement, all disputes under this Agreement shall be governed by binding arbitration pursuant to the mechanism set forth in Article XIII herein. 

14.03 Waiver. Any delay or failure in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or
other matter shall not constitute a waiver of such Party‘s rights to the future enforcement of its rights under this Agreement, nor operate to bar the exercise or enforcement thereof at any time or times thereafter, excepting only as to an
express written and signed waiver as to a particular matter for a particular period of time. 

  
 24 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 14.04 Independent Relationship. Nothing herein contained shall be deemed to create an
employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.
Neither Party shall have any power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

14.05 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information
from the United States of America that may be imposed upon or related to Merck or Licensee from time to time by the government of the United States of America. Furthermore, Licensee agrees that it will not export, directly or indirectly, any
technical information acquired from Merck under this Agreement or any products using such technical information to any country for which the United States government or any agency thereof at the time of export requires an export license or other
governmental approval, without first obtaining the written consent to do so from the Department of Commerce or other agency of the United States government when required by an applicable statute or regulation. 

14.06 Entire Agreement; Amendment. This Agreement, including the Schedules hereto and thereto, sets forth the complete, final and
exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties with
regard to the subject matter of this Agreement in the Territory. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein
and therein. No subsequent alteration, amendment, change, waiver or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

14.07 Notices. Any notice required or permitted to be given or sent under this Agreement shall be hand delivered or sent by express
delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with written confirmation copy by registered first-class mail) to the Parties at the addresses and facsimile numbers indicated below. 

 

			
	if to Licensee, to:                    	  	 Targenics, Inc
 [***]

		
	and:	  	

  
 25 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

			
		
	if to Merck, to:	  	 Merck Sharp & Dohme Corp.

[***]

		
	and	  	 Merck Sharp & Dohme Corp.

[***]

 Any such notice shall be deemed to have been received on the earlier of the date actually received or the date [***]
days after the same was posted or sent. Either Party may change its address or its facsimile number by giving the other Party written notice, delivered in accordance with this Section 14.07. 

14.08 Force Majeure. Failure of any Party to perform its obligations under this Agreement (except the obligation to make payments when
properly due) shall not subject such Party to any liability or place them in breach of any term or condition of this Agreement to the other Party if such failure is due to any cause beyond the reasonable control of such non-performing Party
(“Force Majeure”), unless conclusive evidence to the contrary is provided. Causes of non-performance constituting Force Majeure shall include, without limitation, acts of God, fire, explosion, flood, drought, war, riot, sabotage, embargo,
strikes or other labor trouble, failure in whole or in part of suppliers to deliver on schedule materials, equipment or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of
any government entity acting with color of right. The Party affected shall promptly notify the other Party of the condition constituting Force Majeure as defined herein and shall exert reasonable efforts to eliminate, cure and overcome any such
causes and to resume performance of its obligations with all possible speed; provided that nothing herein shall obligate a Party to settle on terms unsatisfactory to such Party any strike, lockout or other labor difficulty, any investigation or
other proceeding by any public authority or any litigation by any Third Party. If a condition constituting Force Majeure as defined herein exists for more than [***] consecutive days, the Parties shall meet to negotiate a mutually satisfactory
resolution to the problem, if practicable. If the Parties cannot in good faith reach a satisfactory resolution to the problem within [***] days of meeting, the matter shall be handled pursuant to the dispute resolution provisions of Article XIII
herein. 
 14.09 Severability. If any provision of this Agreement is declared illegal, invalid or unenforceable by a court having
competent jurisdiction, it is mutually agreed that this Agreement shall continue in accordance with its terms except for the part declared invalid or unenforceable by order of such court, provided, however, that in the event that the terms and
conditions of this Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Agreement to reasonably substitute such invalid or unenforceable provisions in light of the intent of this Agreement.

  
 26 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 14.10 Counterpart. This Agreement shall become binding when any one or more
counterparts of it, individually or taken together, shall bear the signatures of each of the Parties hereto. This Agreement may be executed in any number of counterparts, each of which shall be an original as against either Party whose signature
appears thereon, but all of which taken together shall constitute but one and the same instrument. 
 14.11 Captions. The captions of
this Agreement are solely for the convenience of reference and shall not affect its interpretation. 
 14.12 Further Actions. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

14.13 Use of Affiliates. Merck and Licensee shall have the right to exercise its rights and perform its obligations under this
Agreement either itself or through any of a Related Party. In addition, in each case where Merck’s or Licensee’s Related Party has an obligation pursuant to this Agreement or performs an obligation pursuant to this Agreement, Merck or
Licensee shall cause and compel such Related Party to perform such obligation and comply with the terms of this Agreement. 

  
 27 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized representatives
of the Parties. 
  

									
	MERCK, SHARP & DOHME, CORP.	 		 	LICENSEE : TARGENICS, INC.
					
	By:	 	/s/ Roger J. Pomerantz	 		 	By:	 	/s/ Martin Oft
					
	Title:	 	SVP WWLKM	 		 	Name:	 	Martin Oft
					
		 		 		 	Title:	 	 
					
		 		 		 	By:	 	/s/ Peter Van Vlasselaer
		 		 		 	Name:	 	Peter Van Vlasselaer
		 		 		 	Title:	 	 

  
 28 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Schedule A 

[***] 
  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	 United
States
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Austria
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Belgium
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	
Germany
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Germany
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/28/2001	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Spain
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
France
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
France
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Ireland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Italy
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Netherlands
	  	9/28/2001	  	[***]	  	[***]	  	[***]

  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	
Australia
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Brazil
	  	9/27/2007	  	[***]	  	 	  	 
	
Canada
	  	9/27/2007	  	[***]	  	 	  	 
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
China
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	
Germany
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Germany
	  	 	  	 	  	[***]	  	 
	
Germany
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Spain
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
France
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
France
	  	 	  	[***]	  	[***]	  	[***]
	
France
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/27/2007	  	[***]	  	 	  	 
	
Italy
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	 	  	 
	
Mexico
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Netherlands
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Norway
	  	9/27/2007	  	[***]	  	 	  	 
	 New
Zealand
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Philippines
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 South
Africa
	  	9/27/2007	  	[***]	  	[***]	  	[***]

  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	
Australia
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Australia
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Canada
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
China
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
China
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	12/15/2009	  	[***]	  	 	  	 
	 Hong
Kong
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
India
	  	12/15/2009	  	[***]	  	 	  	 
	
Japan
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Japan
	  	12/15/2009	  	[***]	  	 	  	 
	
Russia
	  	12/15/2009	  	[***]	  	[***]	  	[***]

 [***] 

  
 29 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Schedule B 

[***] 

  
 30 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Schedule C 
  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	 United
States
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Austria
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Belgium
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	
Germany
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Germany
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/28/2001	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Spain
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
France
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
France
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Ireland
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Italy
	  	9/28/2001	  	[***]	  	[***]	  	[***]
	
Netherlands
	  	9/28/2001	  	[***]	  	[***]	  	[***]

  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	
Australia
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Brazil
	  	9/27/2007	  	[***]	  	 	  	 
	
Canada
	  	9/27/2007	  	[***]	  	 	  	 
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Switzerland
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
China
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	
Germany
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Germany
	  	 	  	 	  	[***]	  	 
	
Germany
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Spain
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
France
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
France
	  	 	  	[***]	  	[***]	  	[***]
	
France
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 United
Kingdom
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 Hong
Kong
	  	9/27/2007	  	[***]	  	 	  	 
	
Italy
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Japan
	  	9/27/2007	  	[***]	  	 	  	 
	
Mexico
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Netherlands
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Norway
	  	9/27/2007	  	[***]	  	 	  	 
	 New
Zealand
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	
Philippines
	  	9/27/2007	  	[***]	  	[***]	  	[***]
	 South
Africa
	  	9/27/2007	  	[***]	  	[***]	  	[***]

  

									
	[***]
	 	 	 	 	 
	Country	  	Application Date	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	
Australia
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Australia
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Canada
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
China
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
China
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	 United
States
	  	[***]	  	[***]	  	 	  	 
	 United
States
	  	[***]	  	[***]	  	[***]	  	[***]
	European Patent Convention	  	12/15/2009	  	[***]	  	 	  	 
	 Hong
Kong
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
India
	  	12/15/2009	  	[***]	  	 	  	 
	
Japan
	  	12/15/2009	  	[***]	  	[***]	  	[***]
	
Japan
	  	12/15/2009	  	[***]	  	 	  	 
	
Russia
	  	12/15/2009	  	[***]	  	[***]	  	[***]

  
 31 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Schedule D 

[***] 

  
 32 

*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]